DiscGenics Completes Patient Enrollment in Japanese Clinical Study of Cell Therapy for Disc Degeneration as US Study Achieves One-Year Follow-up Milestone
DiscGenics, Inc. today announced that it has completed enrollment in its Japanese safety study of IDCT, an allogeneic, injectable Discogenic Cell therapy for lumbar disc degeneration, a major cause of chronic low back pain.
April 27, 2021
by prnasia
Roche ends tominersen study in manifest Huntington’s disease
Swiss pharma company Roche has announced that it will discontinue dosing in a Phase III study evaluating its investigational candidate tominersen in manifest Huntington’s disease.
March 24, 2021
by pharmatimes
Libtayo Monotherapy Trial in Advanced Cervical Cancer Stopped Early for OS Positive Result
Regeneron Pharmaceuticals and Sanofi announced positive results demonstrating an overall survival (OS) benefit from the Phase 3 trial investigating the PD-1 inhibitor Libtayo® (cemiplimab) monotherapy compared to chemotherapy, in patients previously ...
March 22, 2021
by americanpharmaceuticalreview
Libtayo® improves overall survival in advanced cervical cancer patients
A Phase III trial evaluating Libtayo® (cemiplimab) monotherapy in advanced cervical cancer has been stopped early due to a positive result on overall survival.
March 16, 2021
by europeanpharmaceuticalreview
Panel finds efficacy for Regeneron’s REGEN-COV in Phase III Covid-19 trial
Regeneron Pharmaceuticals has announced that Independent Data Monitoring Committee (IDMC) found its REGEN-COV antibody cocktail to have clear clinical efficacy in cutting down the rates of hospitalisation and deaths in patients in a Phase III Covid-19 ...
March 1, 2021
by pharmaceutical-technology
IDMC Concluded Lynparza Trial Crossed Superiority Boundary for Invasive Disease-Free Survival
The OlympiA Phase III trial for AstraZeneca and MSD’s Lynparza will move to early primary analysis and reporting following a recommendation from the Independent Data Monitoring Committee (IDMC).
February 20, 2021
by americanpharmaceuticalreview
Lynparza crosses superiority boundary for invasive disease-free survival at interim analysis
The OlympiA trial will conduct its primary analysis early, after the Independent Data Monitoring Committee found it met its primary endpoint in BRCA mutated early breast cancer patients.
February 19, 2021
by europeanpharmaceuticalreview
IDMC recommends modifications to Regeneron COVID-19 antibody trial
The clinical trial testing the REGN-COV2 antibody cocktail should be altered, according to the Independent Data Monitoring Committee (IDMC).
November 6, 2020
by europeanpharmaceuticalreview
Chi-Med’s Surufatinib Study Meets Primary Endpoint Early
Stops Phase III study of surufatinib in advanced neuroendocrine tumors, meeting the primary endpoint of progression free survival.
July 4, 2019
by contractpharma
IDMC Recommends Stopping Depatuxizumab Mafodotin Study
AbbVie announced the Phase 3 INTELLANCE-1 study of depatuxizumab mafodotin (Depatux-M, previously known as ABT-414) in patients with newly diagnosed glioblastoma (GBM) ...
May 23, 2019
by americanpharmaceuticalreview